Cellect Biotechnology (NASDAQ:APOP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday. The firm currently has a $7.25 price target on the stock. Zacks Investment Research‘s target price points to a potential upside of 10.86% from the company’s previous close.
According to Zacks, “Cellect Biotechnology Ltd. offers biomedical services. It provides stem cell transplantation, disease management, regenerative medicine, clinical research and other services. Cellect Biotechnology Ltd. is based in TEL AVIV, Israel. “
Separately, HC Wainwright set a $14.00 price objective on shares of Cellect Biotechnology and gave the stock a “buy” rating in a research report on Friday, January 5th.
Shares of Cellect Biotechnology stock opened at $6.54 on Friday. Cellect Biotechnology has a 1 year low of $6.12 and a 1 year high of $13.50. The firm has a market cap of $35.58, a price-to-earnings ratio of -4.48 and a beta of 4.62.
Cellect Biotechnology (NASDAQ:APOP) last issued its quarterly earnings data on Monday, March 19th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.15. equities analysts anticipate that Cellect Biotechnology will post -1.3 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Cellect Biotechnology stock. Susquehanna International Group LLP acquired a new position in shares of Cellect Biotechnology (NASDAQ:APOP) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 12,764 shares of the company’s stock, valued at approximately $101,000. Susquehanna International Group LLP owned approximately 0.23% of Cellect Biotechnology at the end of the most recent quarter. 0.62% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/cellect-biotechnology-apop-rating-increased-to-buy-at-zacks-investment-research.html.
About Cellect Biotechnology
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Get a free copy of the Zacks research report on Cellect Biotechnology (APOP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.